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Abstract
Recently, the Vaccines to Vaccinate (v2V) initiative was reconfigured into the Partnership
for Dengue Control (PDC), a multi-sponsored and independent initiative. This redirection is
consistent with the growing consensus among the dengue-prevention community that no
single intervention will be sufficient to control dengue disease. The PDC's expectation is
that when an effective dengue virus (DENV) vaccine is commercially available, the public
health community will continue to rely on vector control because the two strategies comple-
ment and enhance one another. Although the concept of integrated intervention for dengue
prevention is gaining increasingly broader acceptance, to date, no consensus has been
reached regarding the details of how and what combination of approaches can be most ef-
fectively implemented to manage disease. To fill that gap, the PDC proposed a three step
process: (1) a critical assessment of current vector control tools and those under develop-
ment, (2) outlining a research agenda for determining, in a definitive way, what existing
tools work best, and (3) determining how to combine the best vector control options, which
have systematically been defined in this process, with DENV vaccines. To address the first
step, the PDC convened a meeting of international experts during November 2013 in Wash-
ington, DC, to critically assess existing vector control interventions and tools under develop-
ment. This report summarizes those deliberations.
Introduction
Dengue virus (DENV) causes more human morbidity and mortality than any other arboviral
disease. Recent estimates are that approximately 390 million people are infected each year and
96 million manifest with clinically apparent disease [1]. The World Health Organization
(WHO) called for an increased focus on dengue prevention in its 2013 report on neglected
tropical diseases. Dengue’s explosive epidemic potential and the worldwide increase in dengue
cases was noted. Specifically, dengue has experienced a 30-fold increase in incidence over the
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past 50 years that shows no sign of slowing down. The report calls for evaluation and integra-
tion of current intervention strategies to achieve a 50% reduction in dengue mortality and 25%
reduction in dengue morbidity by 2020 [2].
DENV is transmitted from one person to another by Aedesmosquitoes, principally Aedes
aegypti [3]. Human infections can result in a spectrum of diseases ranging from mild, self-
limiting febrile illness to classic dengue fever to shock syndrome and death [4], but it has been
recognized that the majority of infections are mild or show no clinical manifestations. Pres-
ently, there are no commercially available antivirals or dengue vaccines, though progress on
their development is encouraging [5–11]. Dengue prevention, therefore, is currently limited
to mosquito control. A few well-documented successes indicate that rigorously applied vector
control can reduce DENV transmission and disease. During the 1950s and 1960s a regional
program across much of the Caribbean and Central and South America dramatically reduced
Ae. aegypti populations, resulting in striking reductions in human yellow fever and DENV in-
fections and purported elimination of Ae. aegypti from most of the region by the early 1970s
[12,13]. Vector control programs for dengue control in Singapore during the 1970s and 1980s
[14] and in Cuba during the 1980s and 1990s [15–17] are similarly recognized as public health
successes, but they, too, were unfortunately not sustainable. The inability of these countries to
sustain their gains is considered, at least in part, to be the consequence of diminished herd im-
munity [18]. This is worth emphasizing, particularly in the context of envisaged vaccination
programmes, which may help overcome the problem of vector control sustainability by elevat-
ing herd immunity [19]. Less dramatic results, for example during 2000–2010 in Peru, were
seen by the successful use of emergency vector control to reduce the force of DENV infection
[20], i.e., per capita risk of human infection [19]. There is, however, considerable frustration
because vector control has failed to prevent epidemics and DENV’s expanding geographic dis-
tribution [21]. Although the concept of vector control is reasonable, control must be early in
an outbreak or strategically applied during inter-epidemic periods to prevent escalation in
transmission and successful broad scale application has been difficult to achieve (Box 1).
Mission of the Partnership for Dengue Control
The initiative Vaccines to Vaccination (v2V) was established in 2009 to facilitate delivery of
DENV vaccines following regulatory approval. After publication of results from a phase 2b
clinical dengue vaccine trial in Thailand indicating varying levels of vaccine efficacy [9], the
program was reconfigured into the Partnership for Dengue Control (PDC), a multi-sponsored
and independent initiative. Redirection of the program was consistent with the growing con-
sensus among the dengue prevention community that no single intervention will be sufficient
to control dengue disease. This is due to heterogeneities in mosquito vector, viral pathogen,
and human host factors that drive the complexity of transmission. It was decided, therefore,
that, for the greatest likelihood of sustained dengue prevention, the PDC mission should be to
promote development and implementation of multiple innovative, integrated, and synergistic
interventions.
The PDC’s expectation is that when an effective DENV vaccine is commercially available, the
public health community will continue to rely on vector control because the two strategies com-
plement and enhance one another [19]. A dengue vaccine can be used to artificially elevate herd
immunity and vector control to lower the force of infection. Theory and results from field studies
with other vector-borne pathogens support the power of simultaneously targeting the vector and
pathogen. The global malaria burden has been reduced using anti-Plasmodium drugs in conjunc-
tion with insecticide-treated bed nets [22–25]. Lymphatic filariasis (LF) is more rapidly and effi-
ciently managed when anti-parasite drugs are combined with vector control than when drugs
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alone are used [26–32]. As has been the case for malaria and lymphatic filariasis, guidance for
how to best integrate interventions against a complicated, multi-strain pathogen with complex
transmission dynamics, like DENV, will benefit from preliminary, theoretical assessment with
mathematical and simulation models [33,34].
The use of multiple strategies for vector-borne disease prevention is the basis of WHO’s In-
tegrated Vector Management (IVM) program for control of mosquito vectors, including those
that transmit DENV [35]. An element of IVM is decision-making guided by operational re-
search and entomological and epidemiological surveillance and evaluation. The expectation is
that as field data becomes available for dengue vector interventions, so, too, will the ability to
refine guiding principles for implementation and maximizing impact. This evidence will serve
as the basis for assessment, challenging traditional paradigms and changes in the standards for
delivery of vector control and/or vaccines.
As a first step, the PDC initiated a study to assess state-of-the-art vector control for den-
gue. Goals were to critically review different tools and strategies, identify those approaches
with the greatest potential for positive public health impact, identify key missing informa-
tion required for guiding successful vector management, and propose productive ways for
filling knowledge gaps and advancing dengue prevention. This report summarizes those
deliberations.
Box 1. Key Learning Points from Vector Control for Dengue
Prevention
Success in reducing the public health burden of dengue will require a multi-pronged ap-
proach that includes developing the underlying theory of effective dengue control, con-
tinuing to review and assess existing interventions and strategies, and gathering new
empirical data that tests fundamental concepts and strategies. This is best achieved
through:
• Controlled experimental studies are urgently needed to assess the health impact of den-
gue vector control based on epidemiological and entomological metrics. Interventions
under development are required to address this issue. The gap is greatest for existing
tools and strategies, which were developed in an era when epidemiologic assessments
were not carried out.
• Although greater emphasis should be placed on proactive strategies that aim to pre-
vent, diminish, or eliminate transmission, dengue outbreaks occur and response re-
quires attention to development of tools and strategies that can be rapidly deployed
and have swift impact.
• Dengue is a growing problem in modern mega-urban centers that span across coun-
tries and regions. Scaling up from successful small-scale experimental trials to broad-
scale public health application is among the biggest challenges for improving mosquito
control for dengue prevention.
• There is a growing consensus that eliminating dengue as a public health burden can
only be achieved by integrating vector control with vaccines. Prioritizing the vector in-
terventions based on their potential to prevent disease will facilitate determining how
to combine the best options with DENV vaccines.
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Assessment Process
Although the concept of integrated intervention for dengue prevention is gaining increasingly
broader acceptance, to date, no consensus has been reached regarding the details of how and
what combination of approaches can be most effectively implemented to manage disease. To
fill that gap, the PDC proposed a three step process: (1) a critical assessment of current tools
and those under development, (2) outlining a research agenda for determining, in a definitive
way, what existing tools work best, and (3) determining how to combine the best vector control
options, which have systematically been defined in this process, with DENV vaccines. The
PDC convened a meeting of international experts during November 2013 in Washington, DC,
to address the first step, i.e., critically review existing interventions and tools under develop-
ment (Box 2 and Fig 1).
Deliberations fell into three broad categories: (1) current state-of-the-art (existing) in-
terventions, (2) new tools and strategies (methods under development), and (3) mosquito
ecology and modeling. For existing interventions, assessment included which life stage was
targeted and evidence establishing the degree to which the intervention impacts mosquito
populations and DENV transmission (S1 Table). Expectations of impact were based on
available data from small-scale experiments, large-scale field trials, and model results. For
interventions under development, assessment included progress within a product develop-
mental pipeline (S2 Table). Best circumstances were outlined for successful deployment of
all interventions and challenges faced in contexts where an intervention has already been
introduced or is being considered was outlined (S3 Table). Although rigorous economic as-
sessment of each intervention was outside the scope of this workshop, general issues related
to ways that development, delivery, and cost could be improved for each intervention were
explored (S4 Table). Cost-effectiveness will be fundamentally important in the future for
selection and implementation of any vector control intervention.
Existing Tools and Strategies
A list of currently recommended vector control interventions was generated fromWHO guide-
lines for dengue control (S1 Table) [4]. Topical repellents and legislation (regulation) were
added to the list. To streamline discussion, interventions were categorized by tools that: (1)
offer best sustained control, (2) offer best epidemic mitigation, or (3) are politically driven, but
may not provide substantial benefit to reduced disease. The primary assessment criterion of a
single existing strategy was expert opinion regarding evidence of adult vector population re-
duction. The discipline of vector control has been strongly influenced by the theory developed
by Ronald Ross and George Macdonald (i.e., the Ross-Macdonald model), which asserts that
the potential for mosquito-borne pathogen transmission is largely dependent on adult vector
mosquito abundance, survival through the pathogen incubation period, and human-biting rate
[36]. Interventions that reduce adult mosquito population density, daily probability of survival,
and mosquito contact with humans are, therefore, expected to have the biggest impact on de-
creasing virus transmission. It should be noted, however, that the Ross-Macdonald model was
not formulated to specifically explore larval mosquito control. Recent quantitative assessments
indicate that under certain circumstances larval control may result in larger than previously ex-
pected reductions in pathogen transmission [37].
Sustained Management
Tools and strategies recommended by panel participants for sustained dengue mitigation in-
cluded indoor spraying (preferably with residual insecticides) and perifocal spraying with re-
sidual insecticides to kill adult mosquitoes [38]. This is supported by results from the perifocal
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Fig 1. Existing and developing control methods. Existing methods (upper green region) and methods under development (lower yellow region) are
enumerated and separated by those that affect larval mosquito stages (left) and those that affect adult mosquito stages (right). Methods that target a
particular sub-stage within a mosquito’s life cycle are oriented vertically with those sub-stages.
doi:10.1371/journal.pntd.0003655.g001
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residual insecticide treatment of receptacles for the control of larvae and resting adult mosqui-
toes in two successful Ae. aegypti eradication programs in the Northern Territory of Australia
from 2004 to 2006 (Tennant Creek) and from 2006 to 2008 (Groote Eylandt) [39]. Perifocal
spraying, complimented with source reduction, was the mainstay of the eradication campaign
in the Americas. In the Cayman Islands, perifocal spraying was successfully combined with
larviciding, as well as intra- and extra-domiciliary spraying [40]. Although perifocal spraying
of containers that are potential larval development sites with residual insecticide is frequently
promoted in literature on dengue prevention [41], indoor residual insecticide application has
only been carried out on a few occasions as part of a top-down approach for dengue vector
control [42]. Studies of indoor residual spraying (IRS) in Cairns, however, indicate that the
strategy, when used appropriately, (1) reduces adult female density [43] and (2) significantly
reduces DENV transmission risk [44].
Comprehensive container larvicide treatment (with insecticides or biologicals) and con-
tainer removal are recommended for sustained management of immatures, and, thus, indi-
rectly adult Aedes, based on demonstration of small-scale successes using combinations
of interventions [45]. Social mobilization campaigns (education, public relations) [46,47],
environmental management [48], and legislation (enforcement and incentives) were con-
sidered effective as components of sustained mitigation programs [14]. Failure of dengue
vector control strategies has often been associated with the absence of active local commu-
nity involvement [49].
Conversely, two highly visible interventions (aerial and truck mounted ultra-low volume
[ULV] space-spraying) were not recommended due to lack of impact on mosquito population
reduction and lack of cost-effectiveness for routine delivery [50].
Improving sustained mitigation will require a “career structure” that maintains trained staff
through inter-epidemic and epidemic periods. Lack of personnel with appropriate technical
expertise plagues many dengue prevention programs [51]. This could be addressed by generat-
ing permanent positions that, through financial or promotional gains, ensure continuity in op-
erational implementation. Establishing staff work schedules that fit community lifestyles would
facilitate visits to homes and other structures when residents/owners are most likely to be pres-
ent and allow access.
Epidemic Mitigation
Epidemic response tools and strategies can reduce dengue cases. When applied early in the
transmission season (i.e., during the increase of epidemic cases), indoor ULV insecticide
applications were associated with a reduction in the number of dengue cases in Iquitos,
Peru [20]. Similarly, dengue epidemics in Brazil and Hawaii were controlled using indoor
spraying with residual insecticide [52]. The challenge for this approach is early recognition
of increased risk followed quickly by comprehensive broad scale intra-domicile insecticide
application. This is difficult, if not impossible, to accomplish in complex mega-cities. Im-
proved surveillance efforts that guide more logistically feasible spatial and temporal im-
plementation of vector control are needed to improve the speed of response and to elevate
the public health impact of targeted epidemic suppression strategies [19]. In most circum-
stances, as for sustained management, spraying with low-flying aircraft was not considered a
viable approach for epidemic mitigation of dengue.
Under certain specific circumstances, in conjunction with indoor residual spray, personal
repellents (e.g., DEET) and insecticide treated material inside homes (e.g., bed nets and/or
treated lining) where Ae. aegypti rest and bite humans were recognized as a potential compo-
nent of epidemic mitigation. Laboratory studies have shown that Ae. aegypti and Ae. albopictus
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infected with the four DENV serotypes respond similarly to uninfected mosquitoes indicating
that repellents containing DEET may be effective against infective mosquitoes in the field [53].
Field studies in Mexico demonstrated reduction in vector populations using pyrethroid
treated curtains and water jar covers [54]. Data, however, are lacking to assess to what extent
these interventions reduce dengue cases during an epidemic.
At the local level, emergency legislation for immediate access to vacant lots, households,
schools, and/or offices may be required, where not currently enacted, to allow comprehensive
attention to key virus transmission sites.
Perhaps the most important point derived from panel discussions is that the primary reason for
the inability to recommend a specific existing intervention for either sustained management or epi-
demic mitigation is the absence of data providing clear evidence of a direct, positive health impact,
i.e., reduced human dengue cases. For example, no panelist was aware of any controlled study car-
ried out to evaluate the protective efficacy of ULV spraying against human DENV infection despite
the fact that ULV spraying continues to be a frequently used intervention for dengue. The group
recognized that selection and impact of existing, or any, vector control strategy to mitigate vector
populations and/or the overall impact on dengue will be site-specific based on underlying human,
virus, and/or vector dynamics, which is consistent with the requirement for an integrated approach
[54]. Political pressures, however, typically drive implementation of highly visible activities, such
as aerial, truck-mounted, and space-spraying, without a solid empirical basis for using these ap-
proaches to reduce human infection and/or disease.
Interventions Currently under Development
Because, as currently used, existing tools for suppressing dengue vector populations are often
judged ineffective, there has been increasing interest in developing new tools. Some are being
developed by technological improvement of existing approaches. Others involve conceptually
novel approaches that have emerged from breakthroughs in biotechnologies.
Meeting participants developed a list of tools and strategies in development for dengue sup-
pression (S2 Table) that are designed to (1) reduce the overall mosquito population, (2) change
the age structure of the female mosquito population, (3) manipulate female mosquito behavior,
(4) replace wild-type mosquitoes with strains/genotypes that do not transmit DENV, or (5) some
combination of the above. Each tool was evaluated based on criteria related to the (1) current
stage of development, (2) predicted efficacy, (3) expected limitations, and (4) potential for inte-
gration with other tools.
Population Reduction
Synthetic insecticides have long been used to suppress mosquito populations, but negative envi-
ronmental and health impacts, lack of intrinsic efficacy, and evolution of insecticide-resistant
mosquitoes are challenging current insecticide-reliant strategies [55–59]. Two major paths for al-
leviating these problems come from investment in new chemical classes of insecticides [60] and
“molecular insecticides” that use specially engineered nanoparticles to target insecticides at spe-
cific insect tissues and protect the active ingredient from environmental degradation [61]. There
have been major investments in developing and testing new insecticides within existing chemi-
cal classes (and in new classes) with low off-target effects and long residual efficacy. Some of the
first products from these efforts are expected to be field tested in the near future, and completely
novel compounds should soon follow. The goal is to have a tool(s) that is as effective at suppress-
ing DENV transmission as DDT was (high kill and/or repellent with effectiveness for six months
or more), but without associated health or environmental impacts. Early indications are encour-
aging, but it is too soon to draw firm conclusions about the potential for reaching that goal. As
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003655 May 7, 2015 7 / 19
with any intervention that poses a potential selection pressure on mosquito populations, be-
havioral or physiological, monitoring for change in efficacy over time will be a vital part of the
strategy.
There are a number of tools in the pipeline that involve using insect genetic engineering for
population reduction. The one furthest in development is an Ae. aegypti strain engineered by
the start-up company, Oxitec, that has conditional lethality (RIDLR) [62]. The genetically en-
gineered strain can be reared to high numbers in captivity simply by adding tetracycline to the
larval diet. When transgenic males are released into wild-type mosquito populations in the
field and mate with normal females, almost 100% of the offspring are expected to die during
late larval development stages. Data from small-scale trials indicate that wild populations can
be suppressed, but suppression takes a number of months and requires continual release of
the transgenic strain. This approach is expected to work best when the initial population is at
low density and the treatment area is relatively small. Thus, this approach could be used with
other tools that decrease vector population size before RIDLR mosquitoes are released. Prom-
ising results were obtained from field trials in Malaysia and the Cayman Islands [63,64] and
small Brazilian communities [65,66]. As for any transgenic mosquito strain, public acceptance
and regulatory approval will be required.
A public/private partnership (Gates/Oxitec) developed a different transgenic Ae. aegypti
strain (OX36404C) in which only the females die (fsRIDL) when tetracycline is removed from
their larval diet [67]. Such a strain could be more effective than one in which both sexes die. Al-
though indoor large-cage trials were successful [68], results from an outdoor field-cage trial in
Mexico were disappointing [69]. Lowered mating competitiveness of transgenic males was one
cause of the failure of that trial. It is possible that new strains with this female-killing transgenic
construct may have better performance. Detailed population dynamics models indicate that
mosquito suppression with this female-killing technique may be problematic in heterogeneous
city settings and that attention must be paid to developing effective male release methods [70].
Some researchers also question the feasibility of RIDL for large cities or large geographic areas
due to logistic challenges of delivery and concerns about cost. The developers, however, argue
that these obstacles can be overcome [71].
A conceptually similar, but methodologically different, biotechnology approach for popu-
lation reduction would entail multiple releases of male Ae. aegypti artificially infected with a
strain of a microbe,Wolbachia, that renders them 100% reproductively incompatible with
wild-type females [72]. If incompatibility was less than 100%, releases could presumably result
in resurgence of a mosquito population carrying theWolbachia (see below).
Another transgenic method based on sex ratio distortion exploits the specificity of the homing
endonuclease I-Ppol, and is in early stages of development in Anophelesmosquitoes [73]. Using
this approach, a mosquito strain was developed that produces>95%male offspring and has
been shown to suppress caged wild-type mosquitoes following multiple releases. This approach
of sex ratio distortion may provide the foundation for self-perpetuating control of Anopheles if
the DNA sequence causing sex distortion can be inserted on the Y-chromosome. In the future, it
may be possible to develop similar methods for Ae. aegypti that could suppress wild Ae. aegypti
populations based on a single release of a transgenic strain. This is a more daunting challenge
with Ae. aegypti because it lacks a distinct sex chromosome.
In the past few years, a new tool for insect transgenesis and genome editing has emerged.
This tool, based on CRISPR/Cas9 DNA double-strand breaks and repair, has the potential to
substantially propel the field of genetic pest management forward [74,75]. Unlike homing en-
donucleases, in which changing the DNA target site requires major protein engineering, the
CRISPR/Cas9 system enables targeting based simply on changing the nucleotide sequences
coding for guide RNAs. This transforms the whole process of gene manipulation into one that
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is much more efficient and less costly. The CRISPR/Cas9 approach could be used for building
self-perpetuating, sex-biasing Aedes strains or strains that drive a genetic load into an Aedes
population strong enough to cause substantial decline in density, or local elimination.
Attracting and then killing female mosquitoes as they lay eggs, via lethal ovitraps or sticky
gravid traps, is a targeted, alterative strategy for vector population reduction first recognized in
the 1970s [76]. Early attempts in Brazil [77] and Thailand [78] demonstrated reduction in Ae.
aegypti adult and larval populations, but did not meet expectations required for elimination.
More efficient trap designs are currently being developed and evaluated [79]. This includes a
new lethal ovitrap design that was coupled with a bacteria formulation that produces volatile
compounds that are attractive to ovipositing female Ae. aegypti [80–82]. A recent field trial in
Peru generated encouraging preliminary results [83]. Lethal killing stations utilizing adhesives
have also been shown to reduce gravid Ae. aegypti by ~80% in Puerto Rico [79]. Larger, more
comprehensive trials with epidemiologic outcomes are planned.
Other population reduction approaches in early development include mosquitocidal fungus
[84,85]. Mathematical models are being used to assist in optimizing vector population reduc-
tion tools and strategies [86,87]. Early tests of curtains impregnated with insecticide to reduce
mosquito populations in Guatemala were encouraging [54], but a subsequent trial in Thailand
was not successful [88]. Differences in results may have been due to differences in the structure
of houses at the two study locations.
Altered Age Distribution
One strategy, involving insertion of the wMelPop strain ofWolbachia into Ae. aegypti, aims at
shifting the vector population age-structure by reducing the number of females that live long
enough to become infectious and transmit DENV [89]. Output from mathematical models in-
dicates that such aWolbachia strain could reduce dengue transmission [90]. Field tests in Aus-
tralia and Vietnam were, however, disappointing because high fitness costs of the wMelPop
strain to infected Ae. aegypti prevented its establishment [91,92]. New life-shorting strains are
in development, but are not as encouraging asWolbachia-transfected virus refractory strains
discussed below. Transgenic gene-drive constructs tightly linked with effector genes that short-
en life span have been discussed as a control strategy, but none are currently in development.
Behavior Modification
The use of behavior-modifying chemicals and products, such as spatial repellents, that deter
blood-seeking mosquitoes from humans, and, thus, reduce or prevent pathogen transmission,
is receiving increased research attention [93]. Unlike the traditional use of chemicals that are
designed to kill following contact of vectors with a treated surface, these active ingredients are
volatile and are released into a space, such as inside a home, to prevent mosquito entry and/or
disrupt sensory perception required to detect and locate a human host [93,94]. These same
products may also interfere with indoor resting behavior, thereby further enhancing the effect
on adult vector populations due to mosquitoes being forced to search and rest under subopti-
mal environmental conditions required for survival. In Australian houses, metofluthrin has
been shown to rapidly reduce biting and, in some cases, kill adult Ae. aegypti without expelling
them through open windows [95,96]. Field studies in Vietnam have shown densities of adult
Ae. aegypti inside homes treated with metofluthrin plastic latticework strips to be significantly
lower than those in untreated houses for six weeks [97]. Randomized, cluster-controlled trials
using mosquito coils containing either transfluthrin or metofluthrin in China and Indonesia,
respectively, have demonstrated protective efficacy against new malaria infections with an as-
sociated reduction in vector densities and biting rates at sentinel homes, respectively [98,99]. A
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similar, small-scale field trial combining both entomological and epidemiological metrics will
begin soon to evaluate the impact of a similar spatial repellent product to interfere with mos-
quito-human contact in a DENV transmission setting.
Refractory Strains/Genotypes
The most promising near-term approach for rendering mosquito populations incapable of
DENV transmission involves artificial infection with a strain ofWolbachia that does not signif-
icantly impact mosquito life span and, thus, has high fitness, allowing for rapid field establish-
ment [69]. Field trials in Australia and Vietnam are underway, and the strain is well established
in several Australian locations [91,100–106]. Potential for the spread of this strain is being eval-
uated and new strains are in development [91]. Field trials to assess the epidemiologic impact
ofWolbachia-transfected Ae. aegypti on DENV transmission began recently.
An alternative approach is engineering a DNA sequence into the mosquito’s genome that,
when transcribed, produces an RNA molecule that blocks DENV replication. An RNAi trans-
mission-blocking strain for DENV-2 was developed and evaluated in the laboratory [107,108].
No field tests have been conducted. Mathematical models indicate that spreading this trans-
gene into wild populations would require far fewer lab-reared mosquitoes than the conditional
lethal RIDLR approaches, but would likely require continuous releases lasting about one year
[109,110]. These would need to be followed by intermittent releases if there was a small fitness
cost associated with the gene for refractoriness [111]. The current strain only inhibits one of
the four DENV serotypes. Efforts are underway to develop a transgenic strain that does not
transmit any of the DENV serotypes.
Instead of spreading anti-dengue genes into populations through repeated releases, trans-
genic approaches could potentially link an anti-dengue gene with a gene-drive mechanism that
pushes the anti-dengue gene into the mosquito population based on super-Mendelian inheri-
tance. One long-term effort involves a gene drive mechanism, Medea, in which all offspring
from a female die if they do not inherit the gene-drive sequence and the linked anti-dengue
gene [112]. Although this and other gene-drive mechanisms have worked in fruit flies, to date,
they have not been successful in Ae. aegypti. The recent emergence of the CRISPR/Cas9 meth-
odology [74,75], discussed above, has the potential to reinvigorate research aimed at driving
anti-dengue genes into Aedes populations.
Considerations regarding Entomological Endpoints of Health Impact
Panel members recognized that critical to the evaluation of new vector control strategies current-
ly under development, as well as a limitation of previous efficacy trials, has been the methodolog-
ical challenges of documenting changes in vector densities or other entomological endpoints.
Surveillance for Aedes vectors of dengue has historically concentrated on immature stages, such
as larvae and pupae [113]. This has ranged from container-based indices, such as the Breteau
Index and House index, to pupal demographic surveys. With the exception of pupal surveys, im-
mature container indices have generally failed to correlate well with adult populations, let
yet alone dengue risk [114–116]. Often container and pupal surveys are compromised by un-
known cryptic or inaccessible containers, such as subterranean pits/tanks [117,118] and roof gut-
ters [119], that can serve as major Aedes producers. Recent emphasis has shifted to the measure
of adult populations, especially female Ae. aegypti. The advent of adult sampling methods such
as aspirators [120,121], Biogents Sentinel traps [122], and gravid traps [123–125] allow for rela-
tively simple and inexpensive means to measure actual adult populations. Measurement of adult
female populations provides a much more direct assessment of the impact of interventions on
risk of human DENV infection than do immature mosquito surveys [113,114]. Furthermore,
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003655 May 7, 2015 10 / 19
adult females that are captured can be assayed for virus and biocontrol agents, such asWolbachia
[125]. The highly variable and clumped distribution of Ae. aegypti indicates, however, that trials
need to be sufficiently powered with stratified designs to capture account for this variability.
When considering design, the techniques described above fall into two major categories: house-
to-house surveys and fixed trap methods. Survey methods, although more susceptible to operator
variation, can often cover more houses per unit time (often better spatial coverage) than fixed
trap methods, which better capture short-term temporal variation.
Summary and Future Directives
Vector control for dengue can be effective, but, in order for that to happen, implementation
must be done thoroughly, comprehensively, and be sustained. Deliberations at this workshop
were the first in a three-step process that will develop a framework to guide decision-making
on the effective application and integration of dengue vector control interventions. Updating
the assessment of vector control options is desirable given the breadth of currently available
vector control tools; the increasing number of new interventions under development; expecta-
tions that a dengue vaccine will be commercially available in the near future; and the seemingly
unabated, expanding burden of dengue illness.
Decreasing dengue will require increased capacity for informed preventive, versus the cur-
rent reliance on reactive, vector control efforts that use existing and/or novel interventions with
improved, more efficient delivery systems. It is time to stop using interventions simply because
they have been used in the past or because they are politically popular. Many of the current Ae.
aegypti control methods continue to be deployed simply for community visibility without evi-
dence that they prevent disease. The public health cost—benefit of existing tools and strategies
needs to be more clearly defined to reduce dengue at regional and global scales. Limited re-
sources in endemic countries must be more efficiently targeted to only those essential activities
that will have an epidemiologic impact on specific virus transmission scenarios, even if this re-
quires policy changes and results in implementation challenges. For example, given that the vec-
tor control strategies for dengue and chikungunya viruses are broadly similar, the recent and
rapid geographic expansion and intensified transmission of chikungunya virus has cost—benefit
implications for integration of vector and disease management. In many areas, it may be possi-
ble to simultaneously tackle both diseases with the same or similar tools and strategies.
Many of the Ae. aegypti control strategies in development will have time-lagged impacts on
adult populations, i.e.,Wolbachia and transgenics. Those kinds of interventions will be best ap-
plied in sustained, proactive implementation and will likely be inadequate for rapid control of a
developing epidemic. In addition to such proactive strategies, dengue prevention will benefit
from enhanced capacity for outbreak response, before epidemics have peaked and begun to de-
cline on their own. In this regard, spatial repellents, molecular insecticides, and indoor insecticide
application may be particularly amenable to swift deployment with high public health impact.
To reach their full potential for all interventions, proactive and reactive, will require addition-
al thinking about the conceptual basis for strategic innovation, updated guidelines for rigorous
assessment of intervention options, and an expanded prevention toolbox that is supported by
solid empirical data. Funding agencies that are requiring systematic testing and assessment of
novel interventions through the product development pipeline are facilitating these changes.
Conversely, most existing interventions were developed in an era when epidemiologic outcomes
were not emphasized. Understanding when and how existing tools (i.e., indoor application of
existing insecticides) can be best applied will require a shift in attention toward these issues and,
interestingly, can benefit from lessons learned from the newer interventions currently in
development.
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Predicting the effectiveness of existing tools is not currently possible because almost nothing
is known about how well they prevent disease. There is a vital need for robust, rigorously de-
signed field trials with epidemiological and entomological outcomes to improve understanding
of how well existing tools can reduce DENV transmission and their optimal implementation.
Only then can strategy-specific programs be realistically developed and evaluated. Mathematical
models indicate that spatially or temporally targeting existing vector control interventions may
be more effective than applying them evenly across different locations and times [86,126,127].
Likewise, targeting control on mosquito life stages other than adults (larvae and pupae) may be
more effective than previously thought based on the Ross-Macdonald theory [37]. These theo-
retical advances are helpful, but they are not a replacement for results from field studies and,
therefore, new theories require empirical validation.
Among the greatest challenges in dengue vector control is scaling-up local, small-scale suc-
cesses. Ideally, the aim will be to implement an effective intervention, or combination of inter-
ventions, across modern mega-cities as well as large geographic areas that encompass entire
countries and transcend national boundaries. The current inability to effectively scale-up and
predict the public health impact over large geographic areas explains much of the failure of cur-
rent dengue prevention programs, despite their potential to be effective at small scales. This
roadblock must be overcome. Unless effective control can be scaled-up for mega-cities and re-
gional control, the dengue burden will continue to grow.
There is a growing consensus among dengue experts that eliminating dengue as a public
health burden can only be achieved by integrating vector control with vaccines. Integrated
strategies will pose new challenges, such as (1) designing vector control strategies that account
for variation in spatial and temporal patterns in vaccine rollout and the subsequent alterations
that the vaccine may cause in virus transmission dynamics, (2) effective integration of entomo-
logic measures in vaccine trials to guide site characterization and measures of trial impact on
disease, (3) integrating epidemiological indexes to measure the capacity of vector control inter-
ventions to prevent disease, and (4) designing surveillance systems that can distinguish the epi-
demiologic impact of vaccines versus vector control. Addressing these issues will be a central
part of developing a research agenda for assessing the epidemiological impact of the top vector
control candidates, alone and in combination with a DENV vaccine.
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